Athersys Reports Second Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Brent holds above $100 as tanker attacks dampen hopes for Hormuz traffic recovery
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- White House copper tariff plan stalls amid affordability concerns, sources say
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Athersys (ATHX) Misses Q2 EPS by 2c
August 10, 2020 4:01 PM EDTAthersys (NASDAQ: ATHX) reported Q2 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $1.06 million.
Highlights of the second quarter of 2020 and recent events include:
Initiated and advanced enrollment in the Phase 2/3 COVID-19 induced acute respiratory distress syndrome (ARDS) clinical trial (the MACOVIA study) and currently evaluating the safety, tolerability and dose levels of MultiStem® cell therapy in this indication;Continued interactions with the Biomedical Advanced Research and Development Authority (BARDA) regarding a potential collaboration;HEALIOS... More